

FAN MU, PH.D.
Vice President

Direct: 617 425 8279
Fax: 617 425 8001
fan.mu@analysisgroup.com

111 Huntington Avenue
14th Floor
Boston, MA 02199

Dr. Mu specializes in the application of advanced epidemiologic methodologies and biostatistical techniques to address a wide array of analytical questions in health care involving evaluation, decision making, and strategy. She has broad experience designing and implementing advanced and innovative data analytics and solutions for life sciences companies. Dr. Mu's expertise includes real-world evidence development, database analyses, chart review studies, survey research, predictive analytics, systematic and targeted literature reviews, indirect comparisons, and health economic modeling. She has broad experience developing strategies and conducting research to assess the clinical, economic, and humanistic impacts of diseases and treatments in a range of therapeutic areas, including nephrology, immunology, psychiatry, oncology, dermatology, gynecology, and virology. She has consulted to numerous life sciences companies on both novel pipeline agents and products on the market. Dr. Mu's work has supported health care payers and clinical decision makers in both US and global markets. Her research has been published in peer-reviewed journals and presented at clinical and economic research conferences.

EDUCATION

2014 Ph.D., epidemiology, Harvard University
2011 M.S., epidemiology, Harvard University
2009 M.B.B.S., medicine, Peking University

PROFESSIONAL EXPERIENCE

2014–Present Analysis Group, Inc.
Vice President (2022–Present)
Manager (2018–2021)
Associate (2014–2017)

2011–2014 Brigham and Women's Hospital
Research Assistant

2009–2014 Harvard University
Research Assistant, Teaching Assistant

2008–2009 Peking University
Research Assistant

2007–2008 Beijing Shijitan Hospital
Medical Intern

2007 Center for Disease Control and Prevention of Haidian District, Beijing
Intern

ARTICLES AND PUBLICATIONS

1. Chung Y, Maselli DJ, Mu F, Cook EE, Yang D, Young JA, Betts KA, Genofre E, Carstens D. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study. *J Med Econ.* 2023 Jan-Dec;26(1):1-13. doi: 10.1080/13696998.2023.2236867.
2. Lodise TP, Gunter K, Mu F, Gao E, Yang D, Yim E, Sandor S, Berman G. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. *J Manag Care Spec Pharm.* 2023 Aug;29(8):952-964. doi: 10.18553/jmcp.2023.22454.
3. Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO. The Risk of Chronic Kidney Disease Development in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study. *Clin Endocrinol (Oxf).* 2023 Apr;98(4):496-504. doi: 10.1111/cen.14813.
4. Soteris D, Bernstein J, Kanarek H, Mutschelknaus D, Totev T, Chen J, Mu F, Cala ML, Schultz B, Juethner S. Real-world effectiveness of lanadelumab in patients with normal C1-inhibitor hereditary angioedema: A multicenter chart review. *J Allergy Clin Immunol.* 2023 Feb;151(2):AB138. doi: 10.1016/j.jaci.2022.12.432.
5. Pollack CV, Jr., Agiro A, Mu F, Cook EE, Lemus Wirtz E, Young JA, Betts KA, Brahmabhatt YG. Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study. *Expert Rev Pharmacoecon Outcomes Res.* 2022 Dec:1-10. doi: 10.1080/14737167.2023.2161514.
6. Gosmanova EO, Ayodele O, Chen K, Cook EE, Mu F, Young JA, Rejnmark L. Association of Calcium and Phosphate Levels with Incident Chronic Kidney Disease in Patients with Hypoparathyroidism: A Retrospective Case-Control Study. *Int J Endocrinol.* 2022 Nov;2022:6078881. doi: 10.1155/2022/6078881.
7. Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, Swallow E, Gosmanova EO. Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study. *Adv Ther.* 2022 Nov;39(11):5013-5024. doi: 10.1007/s12325-022-02292-1.
8. Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S. Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study. *Adv Ther.* 2022 Aug;39(8):3845-3856. doi: 10.1007/s12325-022-02198-y.
9. Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ. The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States. *Adv Ther.* 2022 Aug;39(8):3547-3559. doi: 10.1007/s12325-022-02202-5.
10. Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, Betts KA, Carstens DD. Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study. *Ann Allergy Asthma Immunol.* 2022 Jun;128(6):669-676.e6. doi: 10.1016/j.anai.2022.02.017.

11. Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. *J Headache Pain*. 2022 May;23(1):56. doi: 10.1186/s10194-022-01415-x.
12. Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. *J Headache Pain*. 2022 Apr;23(1):47. doi: 10.1186/s10194-022-01411-1.
13. Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ. Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis. *Adv Ther*. 2022 Feb;39(2):1033-1044. doi: 10.1007/s12325-021-02017-w.
14. Ayyagari R, Goldschmidt D, Mu F, Caroff SN, Carroll B. An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia. *Clin Psychopharmacol Neurosci*. 2022 Feb;20(1):154-166. doi: 10.9758/cpn.2022.20.1.154.
15. Driessen M, Patterson-Lomba O, Mu F, Thompson S, Seminerio M, Carr K, Sun R, Totev T, Yim E, Ayyagari R, Cohen J. POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting. *Value in Health*. 2022 Jan;25(1):S23. doi: 10.1016/j.jval.2021.11.101.
16. Setyawan J, Billmyer E, Mu F, Yarur A, Zichlin ML, Yang H, Downes N, Azimi N, Strand V. The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases. *Adv Ther*. 2022 Jan;39(1):767-778. doi: 10.1007/s12325-021-02004-1.
17. Setyawan J, Mu F, Zichlin ML, Billmyer E, Downes N, Yang H, Azimi N, Strand V, Yarur A. Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease. *Adv Ther*. 2022 Jan;39(1):738-753. doi: 10.1007/s12325-021-01973.
18. Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E. Determinants of Hyperkalemia Progression among Patients with Mild Hyperkalemia. *Adv Ther*. 2021 Nov;38(11):5596-5608. doi: 10.1007/s12325-021-01925-1.
19. Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ. Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia. *Adv Ther*. 2021 Oct;38(10):5238-5252. doi: 10.1007/s12325-021-01886-5.
20. Davis J, Israni R, Mu F, Cook EE, Szerlip H, Uwaifo G, Fonseca V, Betts KA. Inpatient management and post-discharge outcomes of hyperkalemia. *Hosp Pract (1995)*. 2021 Oct;49(4):273-279. doi: 10.1080/21548331.2021.1925554.
21. Zichlin ML, Mu F, Leo S, Ayyagari R. The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia. *Clin Drug Investig*. 2021 Oct;41(10):853-863. doi: 10.1007/s40261-021-01060-3.
22. Setyawan J, Mu F, Yarur A, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V. Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases. *Clin Ther*. 2021 Aug;43(8):1392-1407.e1. doi: 10.1016/j.clinthera.2021.06.008.
23. Gosmanova EO, Chen K, Ketteler M, Rejnmark L, Mu F, Swallow E, Briggs A, Sherry N, Kaul S. Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. *Adv Ther*. 2021 Aug;38(8):4246-4257. doi: 10.1007/s12325-021-01787-7.

24. Chen K, Joly F, Mu F, Kelkar SS, Olivier C, Xie J, Seidner DL. Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support. *Clin Nutr ESPEN*. 2021 Jun;43:420-427. doi: 10.1016/j.clnesp.2021.03.011.
25. Ketteler M, Chen K, Gosmanova EO, Signorovitch J, Mu F, Young JA, Sherry N, Rejnmark L. Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. *Adv Ther*. 2021 Apr;38(4):1946-1957. doi: 10.1007/s12325-021-01649-2.
26. Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, Briggs A, Ayodele O, Sherry N, Ketteler M. Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. *Adv Ther*. 2021 Apr;38(4):1876-1888. doi: 10.1007/s12325-021-01658-1.
27. Ketteler M, Chen K, Gosmanova EO, Signorovitch J, Mu F, Young JA, Sherry N, Rejnmark L. Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. *Adv Ther*. 2021 Apr;38(4):1946-1957. doi: 10.1007/s12325-021-01649-2.
28. Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D. Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era. *Kidney Med*. 2020 Aug 10;2(5):589-599.e1. doi: 10.1016/j.xkme.2020.06.008.
29. Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ. Prevalence and economic burden of hyperkalemia in the United States Medicare population. *Curr Med Res Opin*. 2020 Aug;36(8):1333-1341. doi: 10.1080/03007995.2020.1775072.
30. Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia. *BMC Psychiatry*. 2020 Jul;20(1):365. doi: 10.1186/s12888-020-02748-0.
31. Ayyagari R, Goldschmidt D, Mu F, Caroff SN, Carroll B. An Experimental Study to Assess the Professional and Social Consequences of Mild-to-Moderate Tardive Dyskinesia. *CNS Spectrums*. 2020 Apr;25(2):275-275. doi: 10.1017/S1092852920000334.
32. Ayyagari R, Thomason D, Mu F, Philbin M, Carroll B. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders. *J Med Econ*. 2020 Feb;23(2):204-212. doi: 10.1080/13696998.2019.1685818.
33. Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. *J Parenter Enterol Nutr*. 2020 Jan;44(1):119-128. doi: 10.1002/jpen.1588.
34. Pozo-Rosich P, Patterson-Lomba O, Mu F, Thompson S, Gandhi S, Doctor T, Bousleiman S, Yang R, Cohen JM. Reductions in headache impact test (HIT-6) scores with fremanezumab and erenumab among patients with episodic migraine (EM) and 24 prior treatment failures: A network meta-analysis. *J Neurol Sci*. 2019 Oct;405:52-53. doi: 10.1016/j.jns.2019.10.1655.
35. Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. Impact of hidradenitis suppurativa on work loss, indirect costs and income. *Br J Dermatol*. 2019 Jul;181(1):147-154. doi: 10.1111/bjd.17101.
36. Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K. The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States. *Mov Disord*. 2019 Feb;34(2):236-245. doi: 10.1002/mds.27579.

37. Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. *Curr Med Res Opin.* 2018 Jun;34(6):971-978. doi: 10.1080/03007995.2018.1433141.
38. Chen K, Mu F, Swallow E, Zhao J, Wang J, Krasner A, Sherry N, Signorovitch J. Comparison of 3-year estimated glomerular filtration rates between recombinant human parathyroid hormone (1-84) (RHPH[1-84])-treated patients with chronic hypoparathyroidism and a historical control cohort. *Endocr Pract.* 2018 Apr;24:111. doi: 10.1016/S1530-891X(20)47188-5.
39. Mu F, Harris HR, Rich-Edwards J, Hankinson SE, Rimm E, Spiegleman D, Missmer SA. A Prospective Study of Inflammatory Markers and Risk of Endometriosis. *Am J Epidemiol.* 2018 Mar;187(3):515-522. doi: 10.1093/aje/kwx272.
40. Farland LV, Mu F, Eliassen H, Tworoger S, Hankinson S, Missmer S. Menstrual cycle characteristics in relation to plasma steroid hormone, prolactin, and growth factor concentrations in premenopausal women. *Cancer Causes Control.* 2017 Dec;28(12):1441-1452. doi: 10.1007/s10552-017-0971-2.
41. Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The Cost of Hyperkalemia in the United States. *Kidney Int Rep.* 2017 Nov;3(2):385-393. doi: 10.1016/j.ekir.2017.11.003.
42. Mu F, Rich-Edwards J, Rimm E, Spiegleman D, Forman J, Missmer S. Association Between Endometriosis and Hypercholesterolemia or Hypertension. *Hypertension.* 2017 Jul;70(1):59-65. doi: 10.1161/HYPERTENSIONAHA.117.09056.
43. Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ. Real-world costs of ischemic stroke by discharge status. *Curr Med Res Opin.* 2017 Feb;33(2):371-378. doi: 10.1080/03007995.2016.1257979.
44. Harris H, Costenbader KH, Mu F, Kvaskoff M, et al. Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis in the Nurses' Health Study II. *Ann Rheum Dis.* 2016 Jul;75(7):1279-84. doi: 10.1136/annrheumdis-2015-207704.
45. Mu F, Rimm E, Rich-Edwards J, Spiegleman D, Missmer S. Endometriosis and Risk of Coronary Heart Disease. *Circ Cardiovasc Qual Outcomes.* 2016 May;9(3):257-64. doi: 10.1161/CIRCOUTCOMES.115.002224.
46. Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. *J Comp Eff Res.* 2016 Mar;5(2):129-39. doi: 10.2217/ce.15.49.
47. Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison. *Clin Ther.* 2016 Feb;38(2):404-12. doi: 10.1016/j.clinthera.2015.12.017.
48. Mu F, Hankinson SE, Schernhammer E, Pollak MN, Missmer SA. A Prospective Study of Insulin-Like Growth Factor 1, Its Binding Protein 3, and Risk of Endometriosis. *Am J Epidemiol.* 2015 Jul;182(2):148-156. doi: 10.1093/aje/kwv037.
49. Kvaskoff M, Mu F, Terry KL, et al. Endometriosis: a high-risk population for major chronic diseases? *Hum Reprod Update.* 2015 Jul-Aug;21(4):500-516. doi: 10.1093/humupd/dmv013.

SELECTED CONFERENCE PRESENTATIONS

1. Banerjee G, Mu F, Cheng M, Cook E, Zhang A, Lan JJ, Zou L, Sikirica V. Economic Burden of Propionic Acidemia by Age Stratum in the United States. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2023, Copenhagen, Denmark. Nov 12–15, 2023
2. Thompson SF, Cohen JM, Sun R, Driessen MT, Seminerio M, Carr K, Mu F. Real-world Effectiveness of Fremanezumab Treatment for Reducing Monthly Migraine and Headache Days in US Patients Having Different Numbers of Prior Migraine Preventive Treatment Failures. ISPOR Europe 2021, Virtual. Nov 30–Dec 3, 2021
3. Driessen MT, Patterson-Lomba O, Mu F, Thompson SF, Seminerio M, Carr K, Sun R, Totev T, Yim E, Ayyagari R, Cohen JM. Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients With Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-world Setting. ISPOR Europe 2021, Virtual. Nov 30–Dec 3, 2021
4. Driessen MT, Patterson-Lomba O, Mu F, Thompson S, Seminerio M, Carr K, Sun R, Totev T, Yim E, Ayyagari R, Cohen JM. Real-world Reductions in Migraine and Headache Days After Initiating Fremanezumab for US Patients With Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway. Virtual. June 3–6, 2021
5. Cohen JM, Thompson S, Patterson-Lomba O, Driessen MT, Seminerio M, Carr K, Mu F. Real-world Data on Reductions in Migraine and Headache Days With Fremanezumab Treatment for US Patients With Chronic and Episodic Migraine: Results From a Physician Chart Review Study. Virtual. June 3–6, 2021
6. Cohen JM, Thompson S, Patterson-Lomba O, Driessen MT, Seminerio M, Carr K, Mu F. US Real-World Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab. 73rd American Academy of Neurology Annual Meeting, Virtual. Apr 17–22, 2021
7. Cohen JM, Thompson SF, Sun R, Driessen M, Seminerio M, Carr K, Mu F. Fremanezumab Treatment Results in Real-world Reductions in Monthly Migraine and Headache Days in Patients Having Different Numbers of Prior Migraine Preventive Treatment Failures in this US Study. Virtual. April 12–16, 2021
8. Chen K, Geller M, Leffler D, Meckley L, Mu F, Kponee-Shovein K, Swallow E. Disease Burden and Quality of Life Impacts in Patients With Celiac Disease on a Gluten-Free Diet: An Analysis of the ICureCeliac Registry. American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, Virtual. Oct 23–28, 2020
9. Yarur A, Setyawan J, Mu F, Zichlin ML, Fernan C, Billmyer E, Downes N, Yang H, Azimi N. The incremental rate of thromboembolic events in patients with inflammatory bowel disease compared to patients without immune-mediated diseases. ACG 2020 Annual Scientific Meeting & Postgraduate Course, Virtual. Oct 23–28, 2020
10. Yarur A, Mu F, Setyawan J, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V. Risk Factors for Thromboembolic Events among Patients with Immune-mediated Diseases. ACG 2020 Annual Scientific Meeting & Postgraduate Course, Virtual. Oct 23–28, 2020
11. Betts KA, Woolley JM, Mu F, Wang Y, Wang Y, Dua A, Wu EQ. Postdischarge Health Care Costs and Readmission in Patients with Hyperkalemia-Related Hospitalizations. American Society of Nephrology (ASN) Kidney Week, Virtual. Oct 19–25, 2020

12. Ayyagari R, Mu F, Lax A, Carroll B. The Impact of Antipsychotic Dose Reduction Within a Medicare Population. International Parkinson and Movement Disorder Society Virtual Congress 2020, Virtual. September 12–16, 2020
13. Venick R, Chen K, Carter B, Hill S, Kocoshis S, Mercer D, Mu F, Swallow E, Zhao J, Wales P, Grimm A. Identification of Factors Associated With Response to Teduglutide Within 24 Weeks Among Pediatric Patients With Short Bowel Syndrome–Associated Intestinal Failure. 11th International Pediatric Intestinal Failure and Rehabilitation Symposium (PIFRS) Virtual Town Hall, Virtual. Jun 26, 2020
14. Cook E, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Pusch A, Yin L, Szerlip H, Uwaifo G, Fonseca V, Wu EQ. Prevalence of Metabolic Acidosis among Patients with CKD and Hyperkalemia. National Kidney Foundation (NKF) 2020 Spring Clinical Meetings, New Orleans, LA. Mar 25–29, 2020
15. Mu F. Indirect comparison of the efficacy of fremanezumab versus erenumab in episodic migraine patients who had failed 2-4 prior migraine preventative treatments. ISPOR Europe 2019, Copenhagen, Denmark. Nov 2–6, 2019
16. Huynh L, Cai B, Lejeune D, Bhak R, Cheng M, Lax A, Duh MS, Kim MK. Real-world adherence, costs, and treatment dosage of patients with neuroendocrine tumors (NET) treated with octreotide or lanreotide. ISPOR 2019, New Orleans, LA. May 18–22, 2019
17. Davis J, Israni R, Betts KA, Mu F, Cook E, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Wu E. Management, Post-Discharge Admission, and Recurrence among Hyperkalemic Patients in the Emergency Department Setting. NKF 2019 Spring Clinical Meetings, Boston, MA. May 8–12, 2019
18. Davis J, Israni R, Betts KA, Mu F, Wang Y, Curhan GC, Anzalone D, Kinrich D, Pusch A, Uwaifo G, Fonseca V, Szerlip H. Outpatient Potassium Monitoring in Hyperkalemic Patients. NKF 2019 Spring Clinical Meetings, Boston, MA. May 8–12, 2019
19. Davis J, Israni R, Betts K, Mu F, Cook E, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Fonseca V, Wu E. Management of Hyperkalemic Patients in the Inpatient Setting by Hyperkalemia Severity. Academy of Managed Care Pharmacy (AMCP) 31st Annual Meeting, San Diego, CA. Mar 25–28, 2019
20. Davis J, Betts K, Mu F, Wang Y, Wang Y. Reduced Renin-Angiotensin-Aldosterone System Inhibitors (RAASi) Use after Hyperkalemia (HK)-Related Hospitalization. AMCP 31st Annual Meeting, San Diego, CA. Mar 25–28, 2019
21. Betts KA, Woolley JM, Mu F, Xiang C, Dua A, Wu EQ. Economic burden of hyperkalemia in medicare patients. ASN Kidney Week 2017, New Orleans, LA. Oct 31–Nov 5, 2017
22. Betts KA, Woolley JM, Mu F, Wang Y, Tang W, Wu EQ. Prevalence of hyperkalemia in Medicare patients. ASN Kidney Week 2017, New Orleans, LA. Oct 31–Nov 5, 2017
23. Betts KA, Woolley JM, Mu F, Kelkar S, Xiang C, Wang Y, Wu EQ. Post-discharge economic burden of hyperkalemia-related hospitalizations. ASN Kidney Week 2017, New Orleans, LA. Oct 31–Nov 5, 2017
24. Betts KA, Woolley JM, Mu F, Bocharova I, Bensimon AG, Wu EQ. Development of a predictive model for hyperkalemia. ASN Kidney Week 2017, New Orleans, LA. Oct 31–Nov 5, 2017
25. Yang M, Mu F, Macaulay D, Kort JJ, Chen YJ. Real-world burden of care for patients with chronic hepatitis C before, during, and after treatment with direct-acting antiviral agents (DAAs). AMCP Nexus 2017, Dallas, TX. Oct 16–19, 2017

26. Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. Hospital utilization rates following antipsychotic dose reductions among patients with schizophrenia. Psych Congress, New Orleans, LA. Sept 16–19, 2017
27. Carroll B, Mu F, Ayyagari R, Gandhi S. Hospital Utilization rates following antipsychotic dose reductions among patients with bipolar and major depressive disorders. Psych Congress, New Orleans, LA. Sept 16–19, 2017
28. Haroon M, Betts KA, Mu F, Skup M, Anderson JK, Joshi AD. Predicting the future development of spondyloarthritis among patients with idiopathic acute anterior uveitis using real-world data. European Congress of Rheumatology, Madrid, Spain. Jun 14–17, 2017
29. Woolley JM, Betts K, Mu F, Xiang C, Tang W, Wu E. Cost of hyperkalemia among patients with heart failure. American Heart Association 2016 Scientific Sessions and Resuscitation Science Symposium, New Orleans, LA. Nov 12–14, 2016
30. Ayyagari R, Alvares L, Mu F, Hacking V, Martinez R, Signorovitch JE. Feasibility of matching-adjusted indirect comparison (MAIC) of omalizumab (OMA) vs. mepolizumab (MEPO) in moderate-to-severe asthma. ISPOR 19th Annual European Congress, Vienna, Austria. Oct 29–Nov 2, 2016
31. Seidner DL, Joly F, Gabe SM, Mu F, Xie J, Kelkar SS, Chen K, Olivier C. Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome. ACG Annual Scientific Meeting, Las Vegas, NV. Oct 21–26, 2016
32. Joly F, Gabe SM, Seidner DL, Mu F, Xie J, Kelkar SS, Chen K, Olivier C. Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome. 24th United European Gastroenterology Week, Vienna, Austria. Oct 15–19, 2016
33. Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhanian A, Wu E. The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure. AMCP Nexus 2016 Conference, National Harbor, MD. Oct 3–6, 2016
34. Betts K, Woolley JM, Mu F, McDonald E, Tang W, Singhanian A, Pham H, Hollenack K, Wu EQ. The Prevalence of Hyperkalemia in the United States. AMCP Nexus 2016 Conference, National Harbor, MD. Oct 3–6, 2016
35. Tzellos T, Ingvarsson G, Yang HB, Mu F, Signorovitch J, Skup M. Salary Growth and Risk of Leaving the Workforce Among Patients With Hidradenitis Suppurativa in the United States. 25th European Academy of Dermatology and Venereology (EADV) Congress, Vienna, Austria. Sept 28–Oct 2, 2016
36. Tzellos T, Ingvarsson G, Yang HB, Mu F, Zhao J, Skup M. Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and Patients' Salary. 25th EADV Congress, Vienna, Austria. Sept 28–Oct 2, 2016
37. Bonnet P, Cloutier M, McKee MD, Loiselle MG, Qian J, Mu F, Qin QQ, Guerin A, Wu EQ, Giranda VL. Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel. American Society of Clinical Oncology (ASCO) 2016 Annual Meeting Chicago, IL. Jun 3–7, 2016
38. Mu F, Hurley D, Betts K, Messali A, Paschoalin M, Wu EQ. Real-world costs of ischemic stroke by discharge status. ISPOR 21st Annual International Meeting Research, Washington, D.C. May 21–25, 2016
39. Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peoples M, Mu F, Noviello S, Signorovitch J. Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in

- patients with chronic hepatitis C coinfecting with HIV: A matching-adjusted indirect comparison. 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015, San Francisco, CA. Nov 13–17, 2015
40. Sail KR, Signorovitch J, Sorg RA, Mu F, Marshall T. Direct and indirect burden of Parkinson's disease on caregivers. International Parkinson and Movement Disorder Society Annual Meeting, San Diego, CA. Jun 14–18, 2015
 41. Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J. Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison. 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2015, Vienna Austria. Apr 22–26, 2015
 42. Mu F, Eliassen H, Tworoger S, Hankinson S, Missmer S. Reproductive history in relation to plasma steroid hormone, prolactin, and growth factor concentrations in premenopausal women. Conjoint Meeting of the International Federation of Fertility Societies and the American Society for Reproductive Medicine (ASRM), Boston, MA. Oct 12–17, 2013
 43. Mu F, Eliassen H, Tworoger S, Hankinson S, Missmer S. Menstrual cycle characteristics in relation to plasma steroid hormone, prolactin, and growth factor concentrations in premenopausal women. Annual Meeting of the Society for Epidemiologic Research, Boston, MA. Jun 18–21, 2013
 44. Mu F, Rimm E, Rich-Edwards J, Spiegelman D, Missmer S. A prospective study of laparoscopically-confirmed endometriosis and risk of hypertension and hypercholesterolemia. Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research, Boston, MA. Jun 17–18, 2013
 45. Mu F, Rimm E, Rich-Edwards J, Spiegelman D, Missmer S. A prospective study of endometriosis and coronary heart disease risk. Annual Meeting of the ASRM, San Diego, CA. Oct 12–17, 2012
 46. Mu F, Hankinson S, Schernhammer E, Missmer S. Endogenous steroid hormone concentrations and risk of endometriosis. Annual Meeting of the World Congress on Endometriosis, Montpellier, France. Sept 4–7, 2011